Rob Dzialo

Robert H. Dzialo

Robert H. Dzialo
+1 617 570 1613

Rob Dzialo is a partner in the firm’s Technology group and Business Law department. Rob primarily advises public and private companies in the technology and life science industries on M&A transactions and has extensive experience representing strategic acquirors and acquisition targets in a wide range of transactions. He also advises clients on an array of corporate matters, including venture capital and growth equity financings, public securities offerings, corporate restructurings and other strategic transactions. Rob joined Goodwin in 2014.

While attending law school, Rob served as a senior editor for the Boston College Law Review.


Rob's client representations include:

Mergers and Acquisitions

Strategic Acquisitions

  • PillPack in its sale to
  • Padlock Therapeutics in its $600 million sale to Bristol-Meyers Squibb
  • PointClickCare in its acquisitions of Patient Pattern and Audacious Inquiry
  • Kabbage in its sale to American Express
  • PTC in its $1.5 billion acquisition of ServiceMax
  • Repligen in its acquisition of FlexBiosys 
  • Sqrrl Data in its sale to
  • in its sale to Facebook
  • HubSpot in its acquisitions of PieSync and The Hustle
  • Toast in its acquisition of Sling

Financial Acquisitions

  • Monotype in its $825 million sale to private equity firm HGGC
  • Acquia in its sale to Vista Equity Partners
  • RedBrick Health in its sale to Marlin Equity Partners
  • Continuum in its sale to Thoma Bravo

Private Financings

  • Bessemer Venture Partners in its equity financing of viagogo in connection with its acquisition of StubHub from eBay
  • Whoop in preferred equity financings totaling over $300 million
  • Century Therapeutics in its $250 million financing led by Bayer
  • CLEAR in its equity financing and strategic collaboration with United Airlines
  • DRIVE by DraftKings in its collaboration with DraftKings, General Catalyst, Accomplice and Boston Seed

Public Offerings

  • Underwriters in Endurance International Group’s follow-on public offerings raising a total of $479 million
  • AMAG Pharmaceuticals in numerous follow-on equity offerings and its high-yield bond offering
  • BridgeBio in its $372 million initial public offering




Boston College

(magna cum laude)


James Madison University

(magna cum laude)



  • Massachusetts

Recognition & Awards

Rob has been recognized by The Best Lawyers in America Ones to Watch for his work in Corporate Law 2022.

Rob was named to The Best Lawyers in America 2021: Ones to Watch.